2 min read

Cleerly to Present on AI-Enabled Heart Disease Solutions at SCCT 2023

Cleerly to Present on AI-Enabled Heart Disease Solutions at SCCT 2023

Cleerly to Present on AI-Enabled Heart Disease Solutions at SCCT 2023
Executives to discuss Cleerly’s end-to-end solution for precision heart imaging to transform cardiovascular care at annual meeting

Denver – July 25, 2023 -- Cleerly, the company creating a new standard of care for heart disease, announced it will be presenting as a Diamond Partner at the Society of Cardiovascular Computed Tomography’s (SCCT) Annual Scientific Meeting, July 27-30 in Boston, MA at the Hynes Convention Center. Onsite, Cleerly executives will highlight the company’s artificial intelligence (AI)-enabled coronary computed tomography angiography (CCTA) solution to help guide personalized evaluation and treatment of coronary artery disease (CAD). For stronger disease tracking, Cleerly’s analysis goes beyond calcium scoring, stress tests and traditional disease markers to truly identify all types of plaque, disease stage, stenoses, plaque burden, and heart health changes over time.

“We are excited to return to SCCT’s 2023 meeting and join the conversation on cardiovascular computed tomography with the best in the industry,” said James K. Min, MD, FACC, FESC, MSCCT, founder and CEO of Cleerly. “It is an honor to continue to attend this event alongside other leaders and faculty in CT technology and share the work we are doing at Cleerly to transform cardiovascular care and provide personalized heart disease evaluation leveraging AI technology.”

During the event, Cleerly will showcase its end-to-end AI solution for precision heart care as well as the future of cardiovascular computed tomography (CT) technology. Additionally, Cleerly will bring attention to the critical role that precisely quantifying plaque can play in comprehensive heart care and preventing heart attacks. As part of the meeting, Cleerly executives will lead an AI and machine learning cardiovascular CT workshop to discuss plaque analysis and other post-processing evaluation developments within the space. The hands-on workshop allows participants the opportunity to work through a theoretical problem considering how to best develop, adjudicate and deploy AI and machine learning in imaging.

Cleerly will be participating in the following sessions:

  • Thursday, July 27: AI/ML Hands-On Workshop
    • Hands On: Imaging Problems and Solutions through AI/ML Model Assessment (9-11:45 a.m. ET) – Cleerly Chief Medical Officer James Earls, MD, FSCCT, will lead the hands-on part of the workshop.
    • Leveraging AI for Comprehensive, Standardized, and Personalized Cardiovascular Care (4-4:15 p.m. ET) – Dr. Min will present on “The Role of AI/ML in Cardiovascular Imaging”.
  • Friday, July 28:
    • 2023 SCCT Clinical Trials and Registries Award (CTRA) Presentation (7:55-9:30 a.m. ET in General Session Rooms 302/304) – Dr. Min will present the Cleerly-supported CTRA plaque and award.
    • Lunch Symposium: “Cleerly: An End-to-End AI Solution for Precision Heart Care” (11:55 a.m.-12:45 p.m. ET in Room 312) – Panel discussion featuring Dr. Min about the critical need for adoption of AI in CCTA analysis to achieve personalized, precision heart care and the research supporting it: 10 million images gathered over a 15-year-period in multi-center clinical trials.
    • Novel Technologies (5:05-6 p.m. ET in General Session Rooms 302/304) – Cleerly executives will join other SCCT Diamond Partners to present their view of the future and what Cleerly believes are the most important aspects of improving cardiovascular CT technology growth and quality.

Those onsite can learn more about Cleerly at booth 200 or schedule a meeting in Cleerly’s private meeting room at this link: https://cleerlyhealth.com/events/scct2023

 


 

About Cleerly

Cleerly is the company creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly helps enable comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: https://www.cleerlyhealth.com.

Cleerly Press Contact:

press@cleerlyhealth.com

 


Resources
SSCT2023 Boston - Cleerly on-site at Booth 200

Download: JPG

Cleerly wordmark: full color (thumbnail)

Download: PNG | EPS

Cleerly wordmark: white (thumbnail)

Download: PNG | EPS

Cleerly iconmark: full color (thumbnail)

Download: PNG | EPS

Cleerly iconmark: white (thumbnail)

Download: PNG | EPS

View more media resources ⇢

Viz.ai and Cleerly Partner on Heart Disease Evaluation Using Artificial Intelligence

Viz.ai and Cleerly Partner on Heart Disease Evaluation Using Artificial Intelligence

New partnership delivers critical insights to more cardiovascular care teams to identify and define atherosclerosis earlier

Read More
Cleerly Welcomes Industry Leaders to Key Executive Positions

Cleerly Welcomes Industry Leaders to Key Executive Positions

Steven Borg joins as CTO, David McGovern as Vice President of Marketing, and Jim Hartman advances to CCO to support company's mission to create a...

Read More
Cleerly® ISCHEMIA™ Demonstrates Robust Diagnostic Accuracy and Prognostic Utility in Analyses from Large Scale Clinical Trials

Cleerly® ISCHEMIA™ Demonstrates Robust Diagnostic Accuracy and Prognostic Utility in Analyses from Large Scale Clinical Trials

CREDENCE and PACIFIC-1 study data demonstrate potential power of AI-QCT ISCHEMIA

Read More
Cleerly to Present New Clinical Evidence on AI-Enabled CCTA at ACC.23/WCC

Cleerly to Present New Clinical Evidence on AI-Enabled CCTA at ACC.23/WCC

Cleerly to Present New Clinical Evidence on AI-Enabled CCTA at ACC.23/WCCResearch shows accuracy and effectiveness of Cleerly’s personalized...

Read More
Cleerly® ISCHEMIA™ Software Device Billable With AMA Category I CPT® Code for Noninvasive Estimates of Fractional Flow Reserve

Cleerly® ISCHEMIA™ Software Device Billable With AMA Category I CPT® Code for Noninvasive Estimates of Fractional Flow Reserve

FDA-cleared Cleerly ISCHEMIA will assist healthcare professionals in clinical diagnosis and decision making for coronary artery disease

Read More
Cleerly Announces CERTAIN Multicenter Clinical Trial Results

Cleerly Announces CERTAIN Multicenter Clinical Trial Results

Study Results Demonstrate the Prominent Effects of Cleerly’s Products on Changing Clinical Management for Patients Suspected of Coronary Artery...

Read More